NanoValent Pharmaceuticals Acquires Targesome, Inc. Intellectual Property

Nanovalent Pharmaceuticals Inc. of Bozeman, Montana has acquired the Targesome intellectual property portfolio. The portfolio consists of eleven patents covering the utilization of polymerized nanoparticles for drug delivery and imaging purposes. Extensive research by Nanovalent attorneys indicate that these patents mark the earliest prior art related to delivery of pharmaceuticals, nucleic acids, and imaging agents using polymerized nanoparticles.

Financial terms of the transaction were not disclosed. Dr. James C. Hamilton, co-founder and president of NanoValent stated, “Securing this family of patents represents achievement of a critical milestone in our intellectual property strategy, and adds significantly to NanoValent’s growing patent portfolio. This should give NanoValent freedom to operate within our domain of polymerized liposomal nanoparticle drug delivery.”

NanoValent is commercializing the Polymerized Liposomal Nanoparticle (PLN) drug delivery platform. The Firm provides custom drug delivery services to private pharmaceutical and academic organizations. NanoValent is currently using proceeds from its custom drug delivery service business to drive three internal development programs. These include a PLN vaccine against Yersinia pestis (NANO-VX), SN38 loaded PLNs to treat Ewing’s Sarcoma (NANO-01), and drug loaded PLNs to treat pediatric Acute Lymphoblastic Leukemia (NANO-03).